Loading stock data…
$2.32-0.09 (-3.73%)
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Sana Biotechnology, Inc. in the Healthcare sector is trading at $2.32 with a market capitalization of $928M. Wall Street consensus targets $8.43 (7 analysts), implying a +263.3% move over the next 12 months. The stock is currently near its 52-week low of $2.32, remaining 33.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.36M↓ | -$43.52M↑ | -$61.20M↓ | -$48.61M↑ | -$65.42M |
| Net Income | -$93.80M↓ | -$42.15M↑ | -$58.83M↓ | -$47.21M↑ | -$63.63M |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including...